English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Tetrahydrocannabinol is a synthetic cannabinoid and its derivatives were first manufactured in Europe in 2004 under the name Bonsai (2). Having the central effects of marijuana, these substances have been introduced as “harmless”, “legal marijuana”, and as “a designed drug” (2). Being readily accessible and cheap, as well as lacking the narcotic substance status, these substances have gained a rapidly increasing popularity, particularly among adolescents and young adults (3,4). Today, synthetic cannabinoids have 11 groups, containing 130 subgroups (5). Although synthetic cannabinoids exert sympathetic effects such as palpitation, sweating, agitation and restlessness, the diversity of synthetic cannabinoid combinations and manufacturing techniques complicate clinical predictions about their effects (6,7). Recently, it has been reported that they cause severe conditions such as myocardial infarction, pulmonary embolism, ischemic stroke, seizure, acute renal failure and death (8-10). Cases of intoxication have also been reported recently due their widespread use (11).

Investigation of the Clinical Course and Outcomes of Bonsai Use